Bristol-Myers Squibb (BMY) launches its $31/share tender offer to buy Amylin Pharmaceuticals (AMLN) in a deal that will extend BMY's portfolio of diabetes treatments. The offer will expire on Aug. 7.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs